Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Director John W. Kozarich sold 2,500 shares of Ligand Pharmaceuticals stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $145.00, for a total transaction of $362,500.00. Following the transaction, the director now owns 33,149 shares in the company, valued at approximately $4,806,605. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ligand Pharmaceuticals Inc. (LGND) opened at $148.90 on Friday. The stock has a market cap of $3,122.56, a price-to-earnings ratio of 111.24, a P/E/G ratio of 1.58 and a beta of 0.91. The company has a quick ratio of 0.95, a current ratio of 0.97 and a debt-to-equity ratio of 0.05. Ligand Pharmaceuticals Inc. has a fifty-two week low of $95.08 and a fifty-two week high of $149.31.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its earnings results on Thursday, November 9th. The biotechnology company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.32. The business had revenue of $33.38 million for the quarter, compared to analyst estimates of $31.04 million. Ligand Pharmaceuticals had a net margin of 12.76% and a return on equity of 7.83%. Ligand Pharmaceuticals’s revenue for the quarter was up 54.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.62 earnings per share. equities analysts expect that Ligand Pharmaceuticals Inc. will post 3.15 EPS for the current year.

LGND has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and set a $157.00 price target on shares of Ligand Pharmaceuticals in a report on Thursday, October 5th. Zacks Investment Research lowered shares of Ligand Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 10th. Roth Capital reiterated a “buy” rating and set a $158.00 price target (up previously from $135.00) on shares of Ligand Pharmaceuticals in a report on Wednesday, October 11th. Craig Hallum reiterated a “buy” rating and set a $170.00 price target (up previously from $160.00) on shares of Ligand Pharmaceuticals in a report on Wednesday, November 15th. Finally, Deutsche Bank lowered shares of Ligand Pharmaceuticals from a “hold” rating to a “sell” rating and set a $105.00 price target on the stock. in a report on Monday, November 20th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $150.67.

Hedge funds have recently added to or reduced their stakes in the stock. 361 Capital LLC acquired a new position in Ligand Pharmaceuticals in the third quarter valued at $2,099,000. Janus Henderson Group PLC lifted its holdings in Ligand Pharmaceuticals by 26.7% in the third quarter. Janus Henderson Group PLC now owns 754,692 shares of the biotechnology company’s stock valued at $102,751,000 after buying an additional 159,201 shares during the period. Round Table Services LLC acquired a new position in Ligand Pharmaceuticals in the third quarter valued at $205,000. Schwab Charles Investment Management Inc. lifted its holdings in Ligand Pharmaceuticals by 15.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 127,792 shares of the biotechnology company’s stock valued at $17,399,000 after buying an additional 17,071 shares during the period. Finally, Prudential Financial Inc. lifted its holdings in Ligand Pharmaceuticals by 48.7% in the third quarter. Prudential Financial Inc. now owns 72,150 shares of the biotechnology company’s stock valued at $9,823,000 after buying an additional 23,643 shares during the period.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/01/13/john-w-kozarich-sells-2500-shares-of-ligand-pharmaceuticals-inc-lgnd-stock.html.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.